Quarterly results round-up: Boston still on road to recovery, Thermo Fisher and Zimmer solid
This article was originally published in Clinica
Boston Scientific has continued to grow during its second fiscal quarter, helping to allay concerns sparked by CEO Ray Elliott's planned departure. He announced in May that he intends to retire at the end of the year, fuelling fears that the company's apparent turnaround could be short-lived, and triggering a drop in the company's share price (www.clinica.co.uk, 11 May 2011).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.